MYC and cancer: However, c‐Myc is currently considered as an ‘undruggable’ or a ‘difficult to drug’ protein owing to its large protein–protein interaction network and lack of protein binding pockets for drugs.[16] Despite efforts to target c‐Myc by different strategies, such as directly inhibiting c‐Myc expression by antisense[17] or small molecules,[18] interrupting the interactions among Myc‐Max‐DNA,[19] and indirectly interfering with c‐Myc‐associated regulators,[20, 21] up to now, identifying an approach to pharmacologically target c‐Myc is still one of the key challenges in cancer research.